Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory [68Ga]Ga-PentixaFor PET in Multiple Myeloma Staging and Treatment Evaluation
2024-516752-18-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Sep 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentixafor in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Primary sensitivity of [68Ga]Ga-PentixaFor PET. Planned start Sep 2021; status: authorised.
02
Drugs
pentixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516752-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516752-18-00.